Pfizer and Arvinas give disappointing breast cancer drug to Rigel

May 12, 2026 11:00 AM EDT Deals Pfiz­er and Arv­inas give dis­ap­point­ing breast can­cer drug to Rigel Lei Lei Wu News Reporter Pfiz­er has turned $1 bil­lion in­to $35 mil­lion. The New York-based phar­ma com­pa­ny and its part­ner Arv­inas are sell­ing rights to their re­cent­ly ap­proved breast … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER